- ReWalk to submit first instances for Medicare protection via Medicare Administrative Contractors (MACs)
- Centers for Medicare and Medicaid Services (CMS) affirms that the MACs have discretion to cowl and reimburse the ReWalk exoskeleton
- CMS additionally plans to additional deliberate on a profit class designation for the ReWalk exoskeleton and has stated that it’ll present extra info within the close to future
MARLBOROUGH, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”, or the “Company”), a number one producer of robotic medical know-how for individuals with decrease extremity disabilities, is asserting that the Company will start submitting Medicare instances following CMS’s September 26, 2022, announcement affirming that the MACs have discretion to cowl and reimburse for the ReWalk exoskeleton. ReWalk Robotics is actively engaged with CMS in its dedication to guage advanced superior applied sciences like exoskeletons.
“We are pleased CMS has provided a pathway to submit cases while they continue to deliberate on the benefit category designation,” stated Larry Jasinski, Chief Executive Officer (CEO) of ReWalk. “In light of this announcement, ReWalk will begin submitting cases for Medicare beneficiaries with spinal cord injury (SCI) to the MACs. All patients with spinal cord injury deserve access to revolutionary technologies that significantly improve their health. We will continue to advocate for Medicare to provide these innovative life-changing devices to beneficiaries with SCI.”
This is the newest step in ReWalk’s efforts to increase entry to the Company’s exoskeletons for Medicare beneficiaries with SCI. Studies have proven that the flexibility to ambulate with an exoskeleton has a profound and helpful impression on well being outcomes for people with SCI, together with via improved psychological well being, elevated gastrointestinal (GI) perform and different enhancements on the well being penalties of a SCI. ReWalk has prioritized working with payers like Medicare to make sure protection of and entry to exoskeleton applied sciences for people who’re paralyzed or disabled resulting from SCI, so they’re able to as soon as once more expertise the well being and well-being advantages of purposeful ambulation.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for people with decrease limb disabilities because of SCI or stroke. ReWalk’s mission is to basically change the standard of life for people with decrease limb incapacity via the creation and improvement of market main robotic applied sciences. Founded in 2001, ReWalk has headquarters within the U.S., Israel and Germany. For extra info on the ReWalk methods, please go to rewalk.com
ReWalk® and ReStore® are registered emblems of ReWalk Robotics Ltd. within the United States and different jurisdictions.
Forward-Looking Statements
In addition to historic info, this press launch accommodates forward-looking statements throughout the that means of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements might embrace projections concerning ReWalk’s future efficiency and different statements that aren’t statements of historic truth and, in some instances, could also be recognized by phrases like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and related phrases or phrases. The forward-looking statements contained on this press launch are primarily based on administration’s present expectations, that are topic to uncertainty, dangers and adjustments in circumstances which might be tough to foretell and plenty of of that are outdoors of ReWalk’s management. Important components that might trigger ReWalk’s precise outcomes to vary materially from these indicated within the forward-looking statements are extra totally mentioned in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), together with the danger components described below the heading “Risk Factors” in ReWalk’s annual report on Form 10-Okay and 10-Okay/A for the yr ended December 31, 2021 filed with the SEC and different paperwork subsequently filed with or furnished to the SEC. Any forward-looking assertion made on this press launch speaks solely as of the date hereof. Factors or occasions that might trigger ReWalk’s precise outcomes to vary from the statements contained herein might emerge occasionally, and it isn’t potential for ReWalk to foretell all of them. Except as required by legislation, ReWalk undertakes no obligation to publicly replace any forward-looking statements, whether or not because of new info, future developments or in any other case.
Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
T: +1 508-281-7274
E: [email protected]
Media Contact:
Anna Sugg
E: [email protected]
